Filtered By:
Specialty: Hematology
Infectious Disease: COVID-19

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 85 results found since Jan 2013.

Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19
Covid-19 has significant implications of hematologic systems, including lymphocytopenia, thrombocytopenia, ischemic or hemorrhagic stroke, pulmonary thromboembolism, and myocardial infarction [1,2]. Iwasaki et al. reported that the pathogen of Covid-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), can induce immune dysfunction, inflammation, and antibody-dependent enhancement by activating host cells via the Fc γIIa receptor in the same way as SARS-CoV-1 [3].
Source: Thrombosis Research - August 2, 2020 Category: Hematology Authors: Ching-Tai Huang, Shao-Yun Hsu, Ko-Wei Chang, Chung-Guei Huang, Cheng-Ta Yang, Ming-Huei Cheng Tags: Letter to the Editors-in-Chief Source Type: research

Thromboembolic events related to atrial fibrillation during the COVID-19 epidemic in Denmark
The COVID-19 epidemic has threatened to overwhelm the health-care systems of European countries resulting in government decisions of extensive societal lockdowns. There have been considerable concerns regarding the collateral effects of the COVID-19 epidemic overshadowing the care of patients with other medical conditions including cardiovascular diseases. Of interest, decreases in the registered incidences of atrial fibrillation (AF) and ischemic stroke have been reported [1,2]. AF is a common reason for physician contact and AF patients are often recommended treatment with oral anticoagulants to mitigate the associated r...
Source: Thrombosis Research - July 29, 2020 Category: Hematology Authors: Peter Vibe Rasmussen, Paul Blanche, Jarl Emanuel Strange, Jawad Haider Butt, Frederik Dalgaard, Kristian Kragholm, Matthew Phelps, Gunnar Gislason, Morten Lock Hansen Tags: Letter to the Editors-in-Chief Source Type: research

Impact of the COVID-19 pandemic on hyperacute stroke treatment: experience from a comprehensive stroke centre in Singapore
AbstractThe Coronavirus disease 2019 (COVID-19) pandemic is rapidly evolving and affecting healthcare systems across the world. Singapore has escalated its alert level to Disease Outbreak Response System Condition (DORSCON) Orange, signifying severe disease with community spread. We aimed to study the overall volume of AIS cases and the delivery of hyperacute stroke services during DORSCON Orange. This was a single-centre, observational cohort study performed at a comprehensive stroke centre responsible for AIS cases in the western region of Singapore, as well as providing care for COVID-19 patients. All AIS patients revie...
Source: Journal of Thrombosis and Thrombolysis - July 12, 2020 Category: Hematology Source Type: research

COVID-19 and ischemic stroke: a systematic review and meta-summary of the literature
We report the pooled incidence of AIS in COVID-19 patients to be 1.2%, with a high mortality rate. Elevatedd-dimer, fibrinogen and the presence of antiphospholipid antibodies appear to be prominent in COVID-19 patients with concomitant AIS, but further mechanistic studies are required to elucidate their role in pathogenesis.
Source: Journal of Thrombosis and Thrombolysis - July 12, 2020 Category: Hematology Source Type: research

Increased rates of hand ischemia following arterial cannulation in patients with severe COVID19-related pneumonia
Thrombotic complications in patients with COVID19 infection are increasingly reported due to the hypercoagulable state induced by the disease [1 –3]. In particular, arterial thromboembolism has been described in up to 4% of patients, with ischemic stroke being the most common thrombotic event [2]. While catheter-related upper extremity venous thromboses are anecdotally reported [4,5], at the moment no reports are available regarding upper extremity arterial thrombosis following cannulation.
Source: Thrombosis Research - June 14, 2020 Category: Hematology Authors: Walter Dorigo, Aaron Fargion, Laura Paperetti, Roberto Falso, Manuela Bonizzoli, Paolo Fontanari, Loredana Poggesi, Carlo Pratesi Tags: Letter to the Editors-in-Chief Source Type: research

Incidence and consequences of systemic arterial thrombotic events in COVID-19 patients
AbstractA high incidence of thrombotic events, particularly deep vein thrombosis and pulmonary embolism, has been clearly documented in COVID-19 patients. In addition, small series of patients with coronary, cerebrovascular and peripheral arterial thrombotic events have also been reported, but their true incidence and consequences are not well described, and constitute the objective of this study. From February 1st to April 21st, 2020, 2115 COVID-19 patients were treated at Hospital Universitario Fundaci ón Alcorcón (Madrid, Spain), and 1419 were eventually admitted. Patient characteristics and outcomes were collected by...
Source: Journal of Thrombosis and Thrombolysis - June 8, 2020 Category: Hematology Source Type: research

Hyperacute multi-organ thromboembolic storm in COVID-19: a case report
We report a 66-year-old female patient with post-mortem diagnosis of COVID-19 who presented progressive livedo racemosa, acute renal failure and myocardial injury, as well as an absence of respiratory symptoms. Transthoracic echocardiography showed severe spontaneous echo contrast in the right cardiac chambers and right-sided cardiac overload presumed to result from pulmonary microvascular thrombosis or embolism.d-dimer levels were increased. The patient developed an acute ischemic stroke and died 2  days following presentation despite therapeutic anticoagulation. Her predominantly thromboembolic presentation supports the...
Source: Journal of Thrombosis and Thrombolysis - June 5, 2020 Category: Hematology Source Type: research

Macrothrombosis and stroke in patients with mild Covid-19 infection.
We describe cases of patients in New York City presenting with stroke secondary to large vessel thrombosis without occlusion, incidentally found to have COVID-19 with only mild respiratory symptoms. This is in contrast to the venous thrombosis and microangiopathy that has been reported in patients with severe COVID-19. Our cases suggest that even in the absence of severe disease, patients with COVID-19 may be at increased risk of thrombus formation leading to stroke, perhaps due to viral involvement of the endothelium. Further systematic study is needed, since this may have implications for primary and secondary stroke pre...
Source: Thrombosis and Haemostasis - May 27, 2020 Category: Hematology Authors: Fara MG, Stein LK, Skliut M, Morgello S, Fifi JT, Dhamoon MS Tags: J Thromb Haemost Source Type: research

Hypercoagulation and Antithrombotic Treatment in Coronavirus 2019: A New Challenge.
Abstract The novel coronavirus 2019 (COVID-19) is clinically characterized by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for a high number of patients needing mechanical ventilation or intensive care units treatment and for the elevated mortality risk. A link between COVID-19 and multiorgan failure may be dependent on the fact that most COVID-19 patients are complicated by pneumonia, which is known to be associated with early changes of clotting and platelet activation and artery dysfunction; these changes may implicate in thrombotic-related events such as myocardial infarct...
Source: Thrombosis and Haemostasis - April 28, 2020 Category: Hematology Authors: Violi F, Pastori D, Cangemi R, Pignatelli P, Loffredo L Tags: Thromb Haemost Source Type: research

Increased prevalence of VTE reported by Klok and colleagues, the numbers don't add up
In this study the authors report that 31% of patients met the composite outcome of having a thrombotic complication which they define as having a pulmonary embolism, deep vein thrombosis, or an ischemic stroke. The study included 184 patients with 31 patients having a thrombotic complication. This adds up to an incidence of 16.8%, not 31%.
Source: Thrombosis Research - April 25, 2020 Category: Hematology Authors: Yonatan Y. Greenstein Tags: Letter to the Editors-in-Chief Source Type: research